M. Dómine Gómez

3.7k total citations
36 papers, 277 citations indexed

About

M. Dómine Gómez is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, M. Dómine Gómez has authored 36 papers receiving a total of 277 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in M. Dómine Gómez's work include Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (14 papers) and Lung Cancer Research Studies (10 papers). M. Dómine Gómez is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (14 papers) and Lung Cancer Research Studies (10 papers). M. Dómine Gómez collaborates with scholars based in Spain, United States and Italy. M. Dómine Gómez's co-authors include Enriqueta Felip, Marina Chiara Garassino, Ruta Slepetis, Pilar Garrido, Bilal Piperdi, Benjamin Besse, Kyle J. MacBeth, Santiago Ponce-Aix, Luis Paz‐Ares and Xiaoling Wu and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and International Journal of Cancer.

In The Last Decade

M. Dómine Gómez

35 papers receiving 272 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Dómine Gómez Spain	9	210	128	73	52	37	36	277
Ying Cheng China	8	211 1.0×	102 0.8×	64 0.9×	31 0.6×	59 1.6×	48	269
Ahmed Bilal Khalid United States	3	145 0.7×	103 0.8×	70 1.0×	54 1.0×	36 1.0×	7	241
Anne Sibille Belgium	9	137 0.7×	83 0.6×	53 0.7×	28 0.5×	29 0.8×	21	204
Elisabetta Gambale Italy	8	178 0.8×	116 0.9×	47 0.6×	40 0.8×	20 0.5×	19	246
Paz J. Vellanki United States	7	160 0.8×	115 0.9×	57 0.8×	41 0.8×	13 0.4×	13	254
Grygorii Ursol United Kingdom	4	233 1.1×	143 1.1×	27 0.4×	54 1.0×	14 0.4×	6	268
Linpeng Zheng China	10	207 1.0×	150 1.2×	77 1.1×	37 0.7×	32 0.9×	17	304
Patricia Martín-Romano France	9	195 0.9×	102 0.8×	114 1.6×	31 0.6×	17 0.5×	29	306
Farah Louise Lim United Kingdom	4	249 1.2×	159 1.2×	25 0.3×	56 1.1×	16 0.4×	7	287
Xiangjuan Ma China	9	274 1.3×	153 1.2×	62 0.8×	53 1.0×	69 1.9×	34	335

Countries citing papers authored by M. Dómine Gómez

Since Specialization

Citations

This map shows the geographic impact of M. Dómine Gómez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Dómine Gómez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Dómine Gómez more than expected).

Fields of papers citing papers by M. Dómine Gómez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Dómine Gómez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Dómine Gómez. The network helps show where M. Dómine Gómez may publish in the future.

Co-authorship network of co-authors of M. Dómine Gómez

This figure shows the co-authorship network connecting the top 25 collaborators of M. Dómine Gómez. A scholar is included among the top collaborators of M. Dómine Gómez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Dómine Gómez. M. Dómine Gómez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Garassino, Marina Chiara, Willemijn S.M.E. Theelen, M. Dómine Gómez, et al.. (2025). 5MO: First-line adagrasib (ADA) with pembrolizumab (PEMBRO) in patients (pts) with advanced/metastatic KRASG12C-mutated non-small cell lung cancer (NSCLC) and PD-L1 ≥50% from the phase II portion of KRYSTAL-7. Journal of Thoracic Oncology. 20(3). S8–S10.

Calvo, Virginia, et al.. (2024). 1284P Clinical utility of liquid biopsy for non-small cell lung cancer patients with ALK fusion variants treated with brigatinib. Annals of Oncology. 35. S819–S819. 1 indexed citations

Aparisi, Francisco, et al.. (2024). 251P Sexual dysfunction in patients with lung cancer: Interim analysis of the LUDICAS study. ESMO Open. 9. 102713–102713. 1 indexed citations

García‐Campelo, Rosario, M. Dómine Gómez, Javier de Castro, et al.. (2023). P2.14-04 Treatment Beyond Progression with Atezolizumab in Extensive-Stage SCLC: Exploratory Analysis from the IMfirst Study. Journal of Thoracic Oncology. 18(11). S372–S372. 2 indexed citations

Bermejo-Peláez, David, Guillermo Gallardo Madueño, Jesús Corral Jaime, et al.. (2023). Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients. Journal of Translational Medicine. 21(1). 174–174. 21 indexed citations

Felip, Enriqueta, Enric Carcereny, Knut B. Smeland, et al.. (2023). 1440P Final top-line results of the BGBC008 phase II, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in second-line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571). Annals of Oncology. 34. S819–S819. 2 indexed citations

Sureda, B. Massuti, et al.. (2023). 187P Tissue B-cell receptor repertoire as biomarker of complete pathological response in NSCLC patients treated with neoadjuvant chemoimmunotherapy (NADIM trials). Journal of Thoracic Oncology. 18(4). S141–S142. 1 indexed citations

Casarrubios, Marta, Alberto Cruz‐Bermúdez, Ernest Nadal, et al.. (2022). 157MO Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy. Annals of Oncology. 33. S105–S105. 1 indexed citations

Campelo, M.R. García, et al.. (2022). 1531P Primary results from IMfirst, a phase IIIb open label safety study of atezolizumab (ATZ) + carboplatin (CB)/cisplatin (CP) + etoposide (ET) in an interventional real-world (RW) clinical setting of extensive-stage small cell lung cancer (ES-SCLC) in Spain. Annals of Oncology. 33. S1246–S1247. 8 indexed citations

10.

Aix, Santiago Ponce, Enric Carcereny, Joaquim Bosch‐Barrera, et al.. (2021). 160P Pembrolizumab re-challenge in patients with relapsed non-small cell lung cancer (NSCLC): A preliminary report of the REPLAY phase II trial - cohort I. Annals of Oncology. 32. S1450–S1450. 5 indexed citations

11.

Sánchez‐Herrero, Estela, Roberto Serna‐Blasco, Rosario García‐Campelo, et al.. (2021). NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment. Molecular Oncology. 15(9). 2363–2376. 14 indexed citations

12.

Blanco, R., Ernest Nadal, M. Dómine Gómez, et al.. (2020). 1317P Survival, quality of life (QoL) and geriatric outcomes of elderly patients (pt) with advanced non-small cell lung cancer (NSCLC), treated with pembrolizumab (P) in the first-line setting. Annals of Oncology. 31. S851–S851. 2 indexed citations

13.

Laza‐Briviesca, Raquel, Alberto Cruz‐Bermúdez, Marta Casarrubios, et al.. (2019). Immune cell biomarkers on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients. Annals of Oncology. 30. v507–v507. 3 indexed citations

14.

Levy, Benjamin, Giuseppe Giaccone, Benjamin Besse, et al.. (2019). Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. European Journal of Cancer. 108. 120–128. 48 indexed citations

15.

Dragnev, Konstantin H., Taofeek K. Owonikoko, Tibor Csőszi, et al.. (2018). Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy. Annals of Oncology. 29. viii597–viii597. 1 indexed citations

16.

Gridelli, Cesare, Tudor–Eliade Ciuleanu, M. Dómine Gómez, et al.. (2017). Randomized double blind phase IIb trial in advanced NSCLC patients who did not progress after first line platinum based chemotherapy: Vx-001, a therapeutic cancer vaccine, vs placebo as maintenance therapy. Annals of Oncology. 28. v638–v638. 3 indexed citations

17.

Thomas, Michael, Santiago Ponce-Aix, Alejandro Navarro, et al.. (2017). Top-line data from the randomized phase 2 IMPULSE study in small-cell lung cancer (SCLC): Immunotherapeutic maintenance treatment with lefitolimod. Annals of Oncology. 28. v539–v539. 5 indexed citations

18.

Font, E. Felip, Scott Gettinger, Scott Antonia, et al.. (2017). Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 28. v462–v462. 22 indexed citations

19.

Gómez, M. Dómine, et al.. (2016). Association of Performance Status and Pain in Metastatic Bone Pain Management in the Spanish Clinical Setting. Advances in Therapy. 34(1). 136–147. 7 indexed citations

20.

Gómez, M. Dómine, et al.. (2010). SEOM clinical guidelines for the treatment of small-cell lung cancer. Clinical & Translational Oncology. 12(1). 27–31. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact